000			03245nam a22003497a 4500
008			210218s20212021 xxu||||| |||| 00| 0 eng d
022			_a2578-5745
024			_a10.1002/acr2.11219 [doi]
040			_aOvid MEDLINE(R)
099			_a33538130
245			_aA Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.
251			_aACR Open Rheumatology. 3(2):116-123, 2021 Feb.
252			_aACR Open Rheumatol. 3(2):116-123, 2021 Feb.
253			_aACR open rheumatology
260			_c2021
260			_fFY2021
265			_sppublish
266			_d2021-02-18
520			_aCONCLUSION: Approximately one-third of patients with pSLE transitioned within the study period. MAP of greater than 0.8 predicted disease evolution into classifiable SLE. Copyright (c) 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
520			_aMETHODS: Patients suspected of SLE were enrolled by lupus experts if they fulfilled three ACR criteria for SLE and were followed for approximately 1-3 years to evaluate transition into ACR-classifiable SLE. Individual cell-bound complement activation products (CB-CAPs), serum complement proteins (C3 and C4), and autoantibodies were measured by flow cytometry, turbidimetry, and enzyme-linked immunosorbent assay, respectively. Blood levels of hydroxychloroquine (HCQ) were measured by mass spectrometry. A multianalyte assay panel (MAP), which includes CB-CAPs, was also evaluated. A MAP of greater than 0.8 reflected the optimal cutoff for transition to SLE. Time to fulfillment of ACR criteria was evaluated by Kaplan-Meier analysis and Cox proportional hazards model.
520			_aOBJECTIVE: To evaluate the usefulness of biomarkers to predict the evolution of patients suspected of systemic lupus erythematosus (SLE), designated as probable SLE (pSLE), into classifiable SLE according to the American College of Rheumatology (ACR) classification criteria.
520			_aRESULTS: Of the 92 patients with pSLE enrolled, 74 had one or two follow-up visits 9-35 months after enrollment for a total of 128 follow-up visits. Overall, 28 patients with pSLE (30.4%) transitioned to ACR-classifiable SLE, including 16 (57%) in the first year and 12 (43%) afterwards. A MAP score of greater than 0.8 at enrollment predicted transition to classifiable SLE during the follow-up period (hazard ratio = 2.72; P = 0.012), whereas individual biomarkers or fulfillment of Systemic Lupus International Collaborating Clinics criteria did not. HCQ therapy was not associated with the prevention of transition to SLE.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aMedicine/Rheumatology
657			_aJournal Article
700			_aCollins, Christopher E
790			_aAlexander RV, Arriens C, Brady K, Collins CE, Conklin J, Kalunian KC, Massarotti EM, Narain S, Putterman C, Ramsey-Goldman R, Saxena A, Wallace DJ, Weinstein A
856			_uhttps://dx.doi.org/10.1002/acr2.11219 _zhttps://dx.doi.org/10.1002/acr2.11219
942			_cART _dArticle
999			_c6160 _d6160